Ann: Trading Halt, page-15

Not saying some aspects of NXS are perfect. We can all improve.

Cut "Proprietary Platform Delivering >90% YoY Sales Growth
1. Total Addressable Market (TAM) based on National Health Statistics Report, February 2017, SmartTRAK, NXS 2
Mission – The development and commercialisation of our proprietary unique non-toxic XBIOTM
technology to reduce the impact of biofilm-based infections in human health
XPERIENCE™
92% growth in 1H
FY23 Product Sales
yoy to US$10.0m
XBIO™ Platform
Deconstructs biofilm,
destroys pathogens, &
defends recolonisation
TAM >US$12.5bn
Across existing
products1
Rapid Growth Direct Sales Channel
226% growth in 1H
FY23 direct product
sales yoy to $7.2m
65% growth yoy in
1H FY23 Direct Sales
Distribution
Direct and partner channels
with increasing focus on
direct channel"

Above is from the 2nd page of the Half Year Results & Capital Raise Presentation linked That page 2 says it so much better than my cut and paste.

My thoughts! It is just a beginning. The Science and demand will be almost overwhelming when the Medical Indemnity industry gets wind of the Easy and Massive savings they will get once wide spread use or even surgically applied use of NXS products impact on re-infections.

Excuse my pun on "surgically applied "

Have a great weekend all